Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) FCF Margin (2019 - 2025)

Historic FCF Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 537.4%.

  • Nurix Therapeutics' FCF Margin fell 1545600.0% to 537.4% in Q4 2025 from the same period last year, while for Nov 2025 it was 313.73%, marking a year-over-year increase of 196600.0%. This contributed to the annual value of 313.73% for FY2025, which is 196600.0% up from last year.
  • As of Q4 2025, Nurix Therapeutics' FCF Margin stood at 537.4%, which was down 1545600.0% from 761.29% recorded in Q3 2025.
  • Nurix Therapeutics' 5-year FCF Margin high stood at 159.01% for Q4 2023, and its period low was 761.29% during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' FCF Margin averaged around 330.51%, with its median value being 351.81% (2025).
  • Per our database at Business Quant, Nurix Therapeutics' FCF Margin plummeted by -12739900bps in 2021 and then surged by 7563800bps in 2023.
  • Nurix Therapeutics' FCF Margin (Quarter) stood at 429.6% in 2021, then crashed by -39bps to 597.38% in 2022, then soared by 127bps to 159.01% in 2023, then tumbled by -341bps to 382.84% in 2024, then tumbled by -40bps to 537.4% in 2025.
  • Its FCF Margin was 537.4% in Q4 2025, compared to 761.29% in Q3 2025 and 149.44% in Q2 2025.